Pulse intravenous cyclophosphamide therapy for dermatologic disorders

Dermatologic Clinics

Volumn 18, Issue 3, 2000, Pages 459-473

  Fox, Lindy P ^b   Pandya, Amit G ^a  

^a Department of Dermatology ^*  (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE;

ALOPECIA; ANAPHYLAXIS; BLOOD TOXICITY; CARDIOTOXICITY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG MECHANISM; GASTROINTESTINAL TOXICITY; HUMAN; HYPERSENSITIVITY; IMMUNOSUPPRESSIVE TREATMENT; LUNG INJURY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REVIEW; SKIN DISEASE; TERATOGENICITY; URINARY TRACT DISEASE; WATER INTOXICATION;

EID: 0033888954     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8635(05)70194-7     Document Type: Article

References (82)

1. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis
2. Cyclophosphamide (Cytoxan): A review on relevant pharmacology and clinical uses
3. Dexamethason-cyclophosphamid-stosstherapie bei blasenbildenden autoimmundermatosen
4. Malignancy following treatment of rheumatoid arthritis with cyclophosphamide: Long-term case-control follow-up study
5. Lupus nephritis
6. The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: A controlled retrospective follow-up
7. Treatment of Behcet's disease
8. Treatment of lupus nephritis: A meta-analysis of clinical trials
9. Cyclophosphamide and hemorrhagic cystitis
10. Return of fertility in a patient with cyclophosphamide-induced azoospermia
11. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotropin-releasing hormone agonist in parallel to chemotherapy
12. Prevention of gonadal damage during cytotoxic therapy
13. Studies on the antidiuretic effect of cyclophosphamide: Vasopressin release and sodium excretion
14. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy
15. Water intoxication following moderate-dose intravenous cyclophosphamide
16. High-dose cyclophosphamide therapy for malignant disease: Toxicity, tumor response, and the effects of stored autologous marrow
17. Chronic herpes gestationis and antiphospholipid antibody syndrome successfully treated with cyclophosphamide
18. Allergic granulomatosis and angiitis (Churg-Strauss syndrome): Response to 'pulse' intravenous cyclophosphamide
19. Alkylating agents and platinum antitumor compounds
20. Drug-induced pulmonary disease: Part 1. Cytotoxic drugs
21. Immunologic effects of plasmapharesis synchronized with pulse cyclophosphamide in systemic lupus erythematosus
22. Drug-induced bladder and urinary disorders: Incidence, prevention, and management
23. Immunosuppressive agents in dermatology: An update
24. Reversal of erythema multiforme major with cyclophosphamide and prednisone
25. Synchronization of plasmapharesis and pulse cyclophosphamide therapy in pemphigus vulgaris
26. A randomized trial of plasmapheresis and subsequent pulse cyclophosphamide in severe lupus: Design of the LPSG trial
27. Sterility and testicular atrophy related to cyclophosphamide therapy
28. Pulse intravenous cyclophosphamide therapy in pemphigus
29. Cyclophosphamide toxicity: Characterising and avoiding the problem
30. Cyclophosphamide in the treatment of toxic epidermal necrolysis
31. Anaphylactic reaction to intravenous cyclophosphamide
32. Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: Comparison of steroids and oral or pulse cyclophosphamide in 25 patients
33. The use of prostaglandin F2 alpha for the prophylaxis of cyclophosphamide induced cystitis in rats
34. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis
35. Les bolus de cyclophosphamide et de methylprednisone dans l'uveite de la maladie de Behcet. Resultants preliminaires comportant l'utilisation de nouveaux criteres d'evaluation
36. Immunomodulating effects of synchronized plasmapharesis and intravenous bolus cyclophosphamide in systemic lupus erythematosus
37. Efficacy of cyclophosphamide in toxic epidermal necrolysis
38. Immunosuppressive agents in dermatology
39. Successful treatment of bullous pemphigoid with pulsed intravenous cyclophosphamide
40. Dexamethasone-cyclophosphamide pulse therapy in pemphigus
41. Hypersensitivity reaction to a metabolite of cyclophosphamide
42. Teratogenic effects of first-trimester cyclophosphamide therapy
43. Cyclophosphamide: Ovarian and other toxicities
44. Indications for, and use of, cytotoxic agents in SLE
45. Immediate hypersensitivity reaction to cyclophosphamide
46. Wegener's granulomatosis: Long-term follow-up of patients treated with pulse cyclophosphamide
47. Successful IV pulse cyclophosphamide in refractory PM in 3 patients with SLE
48. Clinical pharmacology and toxicology of cyclophosphamide: Emphasis on use in rheumatic diseases
49. Chronic immunosuppressive therapy for systemic vasculitis
50. Cyclophosphamide-induced hemorrhagic cystitis in children with leukemia
51. Intravenous pulse cyclophosphamide therapy in myositis and Sjogren's syndrome
52. Transitional cell carcinoma of the renal pelvis associated with cyclophosphamide therapy
53. Lung toxicity associated with cyclophosphamide use: Two distinct patterns
54. Side-effects of intravenous cyclophosphamide pulse therapy
55. Intravenous cyclophosphamide therapy of severe SLE
56. Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide
57. The economic impact of treatment of severe lupus nephritis with prednisone and intravenous cyclophosphamide
58. Clinical pharmacokinetics of cyclophosphamide
59. Severe and prolonged jaundice in a lupus nephritis patient treated with cyclophosphamide
60. Immunoablative high-dose cyclophosphamide without stem cell rescue in paraneoplastic pemphigus: Report of a case and review of this new therapy for severe autoimmune disease
61. Treatment of pemphigus vulgaris with pulse intravenous cyclophosphamide
62. Cicatricial pemphigoid successfully treated with pulse intravenous cyclophosphamide
63. Curative effect of dexamethasone-cyclophosphamide pulse therapy for the treatment of pemphigus vulgaris
64. Curative treatment for pemphigus
65. Intermittent high-dose dexamethasone cyclophosphamide therapy for pemphigus
66. Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus
67. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis: A 20-year follow-up study
68. Intravenous cyclophosphamide pulses in pyoderma gangrenosum: An open trial
69. Optimisation of cyclophosphamide therapy in systemic vasculitis
70. Anaphylactoid reaction with bronchospasm following intravenous cyclophosphamide administration
71. Synchronization of plasmapharesis and pulse cyclophosphamide in severe systemic lupus erythematosus
72. Pulmonary complications of combination therapy with cyclophosphamide and prednisone
73. Preserving ovarian function in patients receiving cyclophosphamide
74. Cyclophosphamide in lupus nephritis
75. Cyclophosphamide-induced hemorrhagic cystitis
76. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener's granulomatosis
77. Antitumor alkylating agents
78. Treatment of rapidly progressive glomerulonephritis due to Behcet's syndrome with intravenous cyclophosphamide
79. Trial of intravenous pulse cyclophosphamide and methylprednisone in the treatment of severe systemic-onset juvenile rheumatoid arthritis
80. Modified oral ondansetron regimen for cyclophosphamide-induced emesis in lupus nephritis
81. Selective effects of cyclophosphamide therapy on activation, proliferation, and differentiation of human B cells
82. Intravenous cyclophosphamide pulses in the treatment of pyoderma gangrenosum associated with rheumatoid arthritis: Report of 2 cases and review of the literature